Seegene, a leading molecular diagnostics company, is set to introduce a fully automated PCR testing system capable of operating 24 hours without human intervention. The company announced Thursday that it will unveil its new unmanned automation platform, CURECA, along with a diagnostic data analytics platform, STAgora, at the upcoming ADLM 2025 conference in Chicago next week.

PCR, or polymerase chain reaction, is a molecular testing method that amplifies DNA to detect specific genetic material. It can identify even trace amounts of viruses by replicating DNA billions of times. Traditional PCR testing requires repetitive manual labor by lab technicians and time-consuming procedures.

CURECA automates every step of the PCR process—from sample storage and preparation to nucleic acid extraction, amplification, and result analysis—enabling continuous 24-hour testing. Its preprocessing module, CURECA Prep, eliminates manual preprocessing steps, enhancing both testing efficiency and consistency, according to the company. This allows lab personnel to focus on higher-level analytical and clinical tasks rather than repetitive physical work.

CURECA is designed to handle highly viscous samples such as urine, stool, sputum, and blood, which have traditionally been difficult to automate. Its modular structure allows flexible configuration for different laboratory environments. Seegene expects the system to be applicable not only to PCR but also to biochemical and immunodiagnostic fields, raising automation standards across diagnostics.

The company also introduced STAgora, a data analytics platform that supports clinical decision-making by analyzing PCR-based diagnostic data. It can track infection trends by region, positive rates by hospital, and patterns of co-infection. Equipped with over 40 analysis tools, STAgora is expected to evolve into a platform that enables personalized care based on diagnostic data.

Seegene is accelerating its global commercialization strategy by selecting partner institutions for pilot programs by year-end. CURECA was first showcased at ESCMID Global 2025 in April, and the company recently established a U.S. subsidiary to strengthen local research and manufacturing capabilities.

“CURECA and STAgora enhance the efficiency of automated testing and data-driven diagnostics,” a Seegene official said. “We plan to expand our global partnerships and continue sharing our technological assets with the international market.”

[ⓒ 매일경제 & mk.co.kr, 무단 전재, 재배포 및 AI학습 이용 금지]